Piermont Capital Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Piermont Capital Management’s Portfolio SGNT Stock Details SGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-116,005	Closed	-$1.41M	–	312
2016 Q1	$1.41M	Sell	116,005 -23,015	-17%	-$323K	0.45%	98
2015 Q4	$2.21M	Sell	139,020 -1,340	-1%	-$21.1K	0.7%	69
2015 Q3	$2.15M	Buy	140,360 +1,980	+1%	+$42.8K	0.7%	75
2015 Q2	$3.36M	Buy	138,380 +21,860	+19%	+$524K	1.02%	16
2015 Q1	$2.71M	Buy	116,520 +102,350	+722%	+$2.71M	0.82%	59
2014 Q4	$356K	Buy	+14,170	New	+$416K	0.13%	148

Other funds holding SGNT

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Piermont Capital Management's SGNT Position: Q2 2016 in Review

Piermont Capital Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q2 2016, closing a stake of 116,005 shares — an estimated $1.41M sold.

Piermont Capital Management first reported a position in SGNT in Q4 2014 and held it in 6 quarters. The position peaked at $3.36M in Q2 2015. 128 funds tracked by Wall St. Rank hold SGNT as of Q2 2016.

Piermont Capital Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q2 2016 after selling out during the quarter.
Piermont Capital Management sold 116,005 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q2 2016, an estimated $1.41M.
Piermont Capital Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q4 2014 and held it in 6 quarters.
Piermont Capital Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $3.36M in Q2 2015.
128 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q2 2016.

Based on Piermont Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.